# Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

> **NCT06908694** · PHASE4 · RECRUITING · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 20 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Semaglutide Pen Injector

## Key facts

- **NCT ID:** NCT06908694
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-02
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06908694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06908694, "Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06908694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*